Leerink Partnrs has cut its Q3 2025 earnings estimate for Regeneron Pharmaceuticals, citing lowered expectations across the ...

The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Shares of Recursion Pharmaceuticals climbed after the company said it has agreed to purchase Rallybio's interest in a drug-development plan that aims to treat a rare genetic bone disease. The stock ...

Shares of ProKidney rose 558% after it reported favorable results from a study of its lead drug candidate, rilparencel, in patients with chronic kidney disease and diabetes.

Mills Wealth Advisors LLC made a calculated move by investing $327,000 in Lockheed Martin during Q1, acquiring 732 shares.